FDA Approves Takeda’s Mimrylo for Rare Blood Cancer
Protagonist TherapeuticsSigSignificance4.09SenSentiment+7.33EnvEnvironment0.00SocSocial+3.74GovGovernance+1.36
Takeda PharmaceuticalSigSignificance3.39SenSentiment+6.15EnvEnvironment+0.03SocSocial+4.00GovGovernance+1.16
The FDA approved rusfertide, branded Mimrylo, a weekly injection for polycythemia vera, a rare slow-growing cancer that causes overproduction of red blood cells and thickens blood. The treatment, cleared to reduce risks tied to blood clots, heart attacks and strokes, will be sold by Takeda after development by Protagonist Therapeutics.
Coverage (8)
- Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder (medcitynews.com)
- Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment (marketbeat.com)
- Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug (benzinga.com)
- Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug (finance.yahoo.com)
- FDA clears Takeda, Protagonist's first-in-class PV drug (pharmaphorum.com)
- US FDA approves Takeda, Protagonist's drug for rare blood cancer (reuters.com)
- US FDA approves Takeda, Protagonist's drug for rare blood cancer (pharma.economictimes.indiatimes.com)
- FDA approves Protagonist and Takeda’s drug for rare blood cancer (statnews.com)